PT  - JOURNAL ARTICLE
AU  - Han, Yang
AU  - Sun, Yujia
AU  - Hsu, Jason C.
AU  - House, Thomas
AU  - Gent, Nick
AU  - Hall, Ian
TI  - Statistical Design and Analysis of Diagnostic Tests for Mutating Viruses
AID  - 10.1101/2021.04.07.21254917
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.07.21254917
4099  - http://medrxiv.org/content/early/2021/10/18/2021.04.07.21254917.short
4100  - http://medrxiv.org/content/early/2021/10/18/2021.04.07.21254917.full
AB  - As the SARS-CoV-2 virus mutates, mutations harboured in patients become increasingly diverse. Patients classified into two strains may have overlapping non-variant-defining mutations.Mutation calling by sequencing is relative to a reference genome. As SARS-CoV-2 mutates, tracking emerging mutant strains may become increasingly problematic if the reference genome remains Wuhan-Hu-1, because the comparison then becomes indirect: current dominant strain relative to Wuhan-Hu-1 versus emerging strain relative to Wuhan-Hu-1.The original Thermo Fisher’s TaqPath PCR test, on which the UK has standardized national testing of SARS-CoV-2 primarily, targets Wuhan-Hu-1. PCR targets appear readily updated, as TaqPath 2.0 now targets both currently known and future SARS-CoV-2 mutations, probing the N gene and ORF1ab but not the S gene, with 8 probes instead of the original 3 probes. Going forward, our statistical method can more directly compare current wildtype versus emerging mutants, since our new method can use any pair of probes updated to probe the current wildtype and anticipated mutations.The fact that patients harbour mixtures of mutations allows our statistical methods to potentially catch emerging mutants. Given a PCR test which targets the current dominant strain (current wildtype), our statistical method can potentially directly differentiate the current wildtype from an emerging strain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe following funding sources are acknowledged as providing funding for the named authors: UK Research and Innovation (UKRI), National Institute for Health Research (NIHR), the Alan Turing Institute for Data Science and Artificial Intelligence and the University of Manchester.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A. No clinical trial involved.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo publicly accessible data is available for sharing.